. . . | --- | --- | |------------------------------------------------------------------|-------| | | | | MGNX DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages | | | MacroGenics, Inc. Investors with Losses in Excess of | | | $100K to Secure Counsel Before Important | | | September 24 Deadline in Securities Class Action - | | September 17, 2024 11:53 AM EDT | Source: The Rosen Law Firm PA New York, New York--(Newsfile Corp. - September 17, 2024) - WHY: Rosen Law Firm, a global investor rights law f ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. So what: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a continge ...

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=102399&from=4 CLASS PERIOD: March 7, 202 ...

Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohort Company expects to have mature median rPFS no later than early 2025 MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ...

Core Viewpoint - MacroGenics, Inc. is facing a class-action lawsuit following a significant drop in its stock price due to safety concerns regarding its experimental cancer drug, vobra duo, which was recommended for discontinuation in a Phase 2 study [1][2]. Group 1: Company Performance and Stock Impact - On July 30, 2024, MacroGenics' shares fell 28% after the Independent Data Monitoring Committee recommended discontinuing vobra duo therapy due to patient safety concerns [1]. - Following the announcement of five patient deaths in the study on May 10, 2024, the company's share price plummeted by $11.36, or about 77% [5]. - Prior to these events, MacroGenics had seen a 30% increase in share price after releasing interim safety data that suggested improved safety with reduced dosing of vobra duo [4]. Group 2: Clinical Trial and Safety Concerns - The TAMARACK study, which is a Phase 2 clinical trial for vobra duo, has been central to the allegations against MacroGenics, with claims that the company misled investors about the drug's safety and efficacy [2]. - Initial positive statements about vobra duo's performance in treating metastatic castration-resistant prostate cancer (mCRPC) were contradicted by later data showing a higher-than-expected rate of serious side effects [3]. - The interim safety data released on April 3, 2024, indicated that reducing the dose and frequency of vobra duo improved safety, but this was followed by negative outcomes that led to the stock's decline [4].

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=101866&from=4 CLASS PERIOD: March 7, 202 ...

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email ...

LOS ANGELES, Sept. 11, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as ...